



Walker, D. A., Meijer, L., Coyle, B. and Halsey, C. (2020) Leptomeningeal malignancy of childhood: sharing learning between childhood leukaemia and brain tumour trials. *Lancet Child and Adolescent Health*, 4(3), pp. 242-250.

There may be differences between this version and the published version. You are advised to consult the publisher's version if you wish to cite from it.

<http://eprints.gla.ac.uk/199600/>

Deposited on: 9 October 2019

Enlighten – Research publications by members of the University of Glasgow
<http://eprints.gla.ac.uk>

Title: Leptomeningeal malignancy of childhood: sharing learning between childhood leukaemia and brain tumour trials.

David A Walker¹, Lisethe Meijer², Beth Coyle¹. & Christina Halsey³

¹Children's Brain Tumour Research Centre, University of Nottingham, School of Medicine, Queen's Medical Centre, Nottingham, NG7 2UH

²Department of Paediatric Neuro-Oncology, Prinses Maxima Center for Paediatric Oncology, Postbus 113, 3720 AC Bilthoven, Netherlands

³Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Gartcube Estate, Switchback Road, Bearsden, Glasgow G61 1QH

Corresponding Author: Professor David A Walker, University of Nottingham,
David.walker@nottingham.ac.uk

Summary (200 words)

Leptomeningeal malignancy (LM) complicates childhood cancers including leukaemias, brain tumours and solid tumours. In leukaemia it is assumed that the malignancy invades the leptomeninges via the vascular route. In brain tumours dissemination from the primary tumour, before or after surgery via the CSF pathways is assumed. However, there is evidence to support the vascular route of dissemination. Success in treating LM represents a rate-limiting step to cure, which has been successfully overcome in leukaemia with intensified systemic, combined with intra-CSF therapy, replacing cranial radiotherapy for the majority. This de-escalated CNS directed therapy is still associated with a degree of neurotoxicity. This balanced benefit justifies exploration of ways to further de-escalate CNS directed therapy. In primary brain tumours standard therapy rely upon cranio-spinal radiotherapy with the attendant risk of acute and delayed brain injury and endocrine deficiencies compounding post radiation impairment of spinal growth. Alternative ways of treating the lepto-meninges by intensifying drug therapy delivered to the CSF are under investigation. Preliminary evidence suggests improved outcomes.

This review seeks to describe the methods of intra-CSF drug delivery, the current drugs in use and consider how the technique may be modified and additional drugs might be selected for this route of administration.

Key Messages

- Cancer affects 1:300 young people by age 20, <60% of whom have leptomeningeal involvement.
- In leukaemias, CNS directed therapy without cranial radiotherapy, has been successful in treating leptomeninges with reduced brain and endocrine consequences for survivors, further de-escalation of CNS directed therapy is being considered
- In brain tumours, cranio-spinal radiotherapy is effective but extremely toxic. Intensifying drug therapy with intra-CSF drug delivery is being explored with promising results.
- Intra-CSF drug delivery in brain tumours is complicated by post-operative changes and the co-existence of ventricular peritoneal shunts.
- Exploring alternative ways of delivering intra-CSF drugs and expanding the range of drug suitable for this purpose are necessary to allow the potential benefits to be offered to all.

Conflict of Interest

The authors declared no conflicts of interest

Background

Cancer affects 1:300 people by aged 2 years, at least two-thirds of whom present a risk of leptomeningeal involvement (LMI) [Charles Stiller, Personal Communication]. When it occurs, it is a rate-limiting step for cure thereby presenting a challenge to the therapist especially in primary brain tumours where the risk of LMI is greatest. Historically, craniospinal radiotherapy has been the standard approach to treating the risk of, and actual LMI, complicating brain tumours. Indeed, it offered the first examples of “cure” in medulloblastoma (1,2) .

Aggressive pre-emptive treatment of LMI has been a routine component of treatment for childhood leukaemias and high-grade lymphomas since the 1970s and is considered essential for cure. Initial use of central nervous system (CNS) targeted radiotherapy was associated with unacceptable long-term cognitive and adverse endocrine effects leading to gradual phasing out of its routine use in first-line therapy. It has largely been replaced with intensified systemic and intracerebrospinal fluid (CSF) therapies. Despite this, CNS-directed therapy remains potentially toxic, with a lack of reliable biomarkers to guide risk-adapted therapies. Thus, the challenge in haematological malignancies is reducing the toxicity of CSF-delivered drug regimens in first line treatment without compromising efficacy.

Risks of radiation therapy to the brain

Extended fields of high dose radiotherapy early in life carry heavy penalties for brain development, affecting the development of normal cognition and memory, limiting spinal growth and damaging endocrine function (particularly growth hormone). The risk of second malignant and benign brain tumours is particularly worrying in disease groups where cure rates now exceed 70% at 5 years and beyond. Scatter dose radiation to non-CNS tissues in the neck, thorax and abdomen increase the volumes of tissue at risk of second tumour development after radiation damage. These penalties are greatest when used in the youngest children with the most tissue development and growth to follow (3). The modification of radiation fields using Intensity-Modulated Radiation therapy (IMRT), tomo-therapy and proton therapy offer reductions in scatter dose radiation and greater precision of tumour bed volumes but cannot compensate for the radiation brain injury within boosted fields, consequent upon cranio-spinal radiotherapy (3,4). The balance of benefits and risks therefore have been difficult to judge in primary brain tumours, in contrast to leukaemia and lymphoma, because the brain needs to be treated vigorously to eradicate the primary tumour with surgery, radiotherapy and possibility of safely reducing the risk of radiation brain injury. Progress has been slow in clinical trials because of the diverse primary brain tumour groups, where optimizing curative therapy in high risk disease was initially prioritized in trial design; subsequently, trials were directed at de-escalating radiation dosing and field volumes by introducing

clinical and molecular risk stratification and compensatory systemic chemotherapy (4).

CSF therapy in Brain Tumours

A recent trial has identified that CSF etoposide (0.25-1mg) given to children and young adults with malignant brain tumours can be combined safely with systemic chemotherapy and radiotherapy using daily or twice daily bolus administration over 5-10 days every 2-5 weeks (5)(Ref). There have also been reports of the use of intra-ventricular methotrexate in patients with metastatic, relapsed or refractory medulloblastoma, which was well tolerated. A meta-analysis identified a correlation between cumulative intra-ventricular methotrexate dosing and improved outcome (6,7). A single arm study in highly malignant atypical teratoid rhabdoid tumours (ATRT) included the use of intra-CSF Cytarabine, methotrexate and hydrocortisone (8) and another is testing intra-CSF Etoposide and Topotecan/ Depocyte® as part of an anti-angiogenic multi-agent regime in relapsed medulloblastoma (8,9). A meta-analysis of intra-ventricular therapy found that intra-ventricular therapy contributed to enhanced survival in Atypical Teratoid Rhabdoid Tumour (ATRT) (10). An international randomized trial investigating the role of CSF delivered methotrexate, in pre-school age children with low risk medulloblastoma was about to be launched but is being reconsidered as a result of the early closure of ACNS 1221 trial (11), which excluded ventricular therapy from the regimen demonstrating an excess of relapses compared to a similar

chemotherapy study including intra-ventricular methotrexate. The SHH biological sub-group in this trial had favourable outcomes and the role of different adjuvant strategies are currently being considered for randomized comparisons where intra-ventricular therapy may be part of the strategy selection (12,13). There is growing evidence therefore that intra-ventricular therapy with the historical drug methotrexate and other drugs can contribute to enhanced outcomes in higher risk malignant tumours types.

Novel methods of CSF drug formulation, delivery or scheduling have not been explored. Possible restraining factors include the rarity of the clinical problem in children compared to adults, where 1:2 people are at risk of cancer and 40% are at risk of LMI. There is also a need to test new systems in children, and the added cost and challenge of international collaboration and pharmaceutical engagement. The scene is set therefore for further investigation of CSF delivered therapy in primary brain tumours, to both enhance tumour control and reduce neurotoxicity in risk-adapted therapies

In this review, we will re-consider the potential for CSF delivered drug therapies in childhood malignancies and discuss how optimization of CSF drug delivery might be explored in future trials of both CNS and haematological malignancies. We will consider haematological malignancies first, as the most progress has been made with these to date.

Leptomeningeal infiltration in haematological malignancies

LMI complicating haematological malignancies is a diffuse and/or multifocal invasion of the leptomeninges at the vascular-meningeal interface (14). Leukaemic blasts are thought to reach the leptomeninges by the vascular route, crossing the blood-CSF barrier, or by direct extension along bridging veins from the adjacent skull and vertebral bone marrow (figure 1) (15,16).

Several lines of evidence suggest that LMI in ALL is significantly underdiagnosed using conventional cyto-morphology (cytospin) and is likely to be present in most children at initial diagnosis (16–18). Indeed, the introduction of universal CNS-directed therapy, irrespective of initial cytospin findings, led to a dramatic improvement in overall survival (OS) from 20-30% to 50-60% in the 1970's (19). Initially radiotherapy was used to treat LMI but high rates of secondary CNS malignancies and endocrinopathies led to a switch to targeted treatment with intensified methotrexate or triple intrathecal therapy (methotrexate, cytarabine and steroids), alongside systemic drugs with good CNS penetration. This approach has reduced CNS relapse to less than 5% and increased OS rates >90% (20). However significant methotrexate-related neurotoxicity still occurs. Acute neurotoxicity includes headaches, somnolence, seizures, or methotrexate

“stroke-like syndrome” (19). In addition, methotrexate has been implicated as one of the causative agents for chronic neurocognitive defects seen in up to 50% of children post ALL therapy ((21,22)). Efforts are now concentrating on reducing the burden of CNS-directed therapy by improved systemic control, and more sophisticated methods to monitor the response of LMI to the delivered therapies to allow tailoring of treatment intensity to a child’s individual risk of CNS relapse. Refractory and/or relapsed CNS leukaemia can be very challenging to treat and novel agents with a reduced toxicity profile for these heavily pre-treated patients would be advantageous. These include liposomal cytarabine and immunotherapies such as CAR-T cells and bi-specific antibodies.

Leptomeningeal infiltration in primary brain and other solid tumours

LMI has a similar pathological appearance in primary brain malignancies. In medulloblastoma, the commonest childhood malignant brain tumour, 30% present with LMI (23) and 60% have LMI at relapse (24). All are treated assuming LMI is a risk. A recent study by Zapotocky et al. has however suggested that group 3 tumours tend to show laminar (diffuse) metastatic dissemination, group 4 tumours show a mixture of laminar and focal metastases and sonic hedgehog tumours are associated with multifocal lesions. Thus, the pattern of metastasis appears to be linked to the underlying molecular drivers of the disease and may also link to outcome (25). LM disease has been found to differ in its molecular profile from the primary tumour suggesting clonal selection as part of process of dissemination

(4,26–28). Thus, metastatic tumours have either diverged prior to treatment or been selected and expanded as a result of treatment. In either case, the resultant leptomeningeal metastasis has genetically diverged and is unlikely to respond to same targeted treatment as the tumour of origin. Leptomeningeal dissemination has traditionally been hypothesized to be via the CSF whereby cells enter the CSF at the tumour : CSF interface or after surgical disruption during tumour resections. Recent evidence has, however, identified that there may be a proportion of cases where tumour cells reach the LM via the vascular route as in leukaemia / lymphoma (29,30). These alternatives routes of dissemination to LM would justify the use of both systemic and CSF delivered drugs in their prevention and treatment. Although not necessarily the same targeted drug since both may have evolved.

Treatment Considerations

Cytotoxic concentrations in the CSF of systemically administered drugs are compromised by the blood-brain-barrier and blood-CSF barrier. Drug transfer from blood to CSF is compromised by tight junctions between the capillary endothelial cells (31,32). This barrier can be overcome by choosing drugs with specific physical and pharmacological characteristics including: low molecular weight (<500 kDa), high lipid solubility (33), structures with few nitrogen and oxygen atoms (preferably <8-10), small physical size <11 nm, low protein binding and hydrogen bonding (33). Drug penetration of CSF is also inhibited by

drug influx and efflux transporters, increased interstitial pressure of brain and tumour and reduced blood flow in the tumour (34). Intra- and extracellular enzymes may inactivate or be required to activate compounds.

One approach to this poor penetration of drugs into the CSF is to use exceptional systemic dosing such as high dose methotrexate with folinic acid rescue in leukaemias (35) or high dose multi-agent chemotherapy with stem cell rescue in brain tumours (36) to try and achieve higher concentrations of cytotoxic drugs within the CNS. Alternatively, intra-CSF administration is a method to circumvent these barriers, as was observed in a study in brain tumour patients where systemic HD-etoposide (400 mg/m^2 over 96 hours) was administered as part of intensified systemic therapy. This schedule failed to achieve a cytotoxic CSF concentration ($>0.1 \text{ } \mu\text{g/ml}$) (37), whilst the same drug Etoposide administered into CSF at 0.5 mg daily for 5 days achieved a CSF concentrations at more than 100-fold the level achieved by systemic administration with negligible systemic or CNS toxicity.

The successful use of intra-CSF therapy in childhood leukaemia / lymphoma is notable. Although the choice of agents that are suitable for intra-CSF delivery and also effective against leukaemia has severely limited the selection of drugs for testing in primary brain tumour indications, The only new drug in the past four decades developed for this route of administration is liposomal cytarabine

(Depocyte®). On the one hand, it has an attractive pharmaceutical profile because of its sustained release pattern reducing the need for repeated lumbar puncture; on the other hand, arachnoiditis side effects requiring concomitant steroids, coupled with its high cost and complex manufacturing process has resulted in its recent withdrawal from the market (38).

The lack of new drug development has led researchers to explore existing chemotherapy agent's suitability for administration via the CSF, mainly off license. Their selection being justified by pharmacological principles and published evidence. Shortlists of existing agents have been drawn up for primary brain tumours and preliminary trials of their use have been reported (39). A key feature has been to select drugs with no evidence of neurotoxicity, as direct administration to the CSF will bring the drug into direct contact with brain at CNS concentrations exceeding that achieved by systemic routes. Using this approach, methotrexate was excluded as a suitable candidate because of the extensive evidence of its neurotoxicity especially in previously irradiated patients. A UK national guideline has specified intra-CSF methotrexate in favourable risk medulloblastoma in pre-school age children (13,40). Neurotoxicity of this approach is, therefore, anticipated but may be difficult to attribute to the drug as opposed to the toxicity of delayed diagnosis, surgical interventions and systemic chemotherapy (41). This could be the focus of future randomized trials.

Optimising LM-directed drug therapy

The requirements for LM-directed therapy are: maintaining an optimized therapeutic concentration at the tumour site, with acceptable systemic and neurotoxicity (42) to eradicate tumour cells in order to stabilise tumour-related neurological signs, while maintaining quality of life and, where highly effective, prolonging survival (43).

To optimize intra-CSF chemotherapy efficacy, CSF flow characteristics and drug pharmacokinetics need to be taken into account.

CSF distribution volume is static in children over 3 years of age at 110-150 ml (44). Intraparenchymal penetration of intra-CSF administered drugs is limited to 2-3 mm (45). Characteristics favouring CSF drug delivery include direct contact with tumour cells, small CSF volume of distribution and the absence of a first pass effect. This allows very low drug dosages to achieve cytotoxic levels in the CSF, thereby avoiding systemic toxicity.

CSF velocity, and therefore speed of mixing and dissemination of drug administered to CSF spaces, is determined by the choroid plexus flow. This is amplified by a pulsatile CSF motion (caused by blood flow and breathing pattern) (46) at an average of 0.35 mL/min (34), occupying the entire CSF space in 5-7

hours (47), thus exchanging the entire CSF volume four times a day. This is referred to as bulk flow. The clearance rate limits drug-to-tumour exposure time, which theoretically could compromise the efficacy of cell-cycle dependent drugs such as MTX, etoposide and cytarabine. Solid tumours have slower proliferation rates where prolongation of contact between drug and tumour would be theoretically advantageous.

Where physiological CSF flow is from choroid plexus in lateral, third and fourth ventricles to the arachnoid granulations in the superior sagittal sinus, the most efficient administration route is by intra-ventricular route with the drug flowing with the CSF bulk flow. This route of administration requires an intraventricular catheter such as an Ommaya reservoir. This is an implantable device consisting of a small capsule situated between the skull and overlying scalp connected to a catheter communicating directly with one of the lateral ventricles (48–50).

This permits painless access to the ventricular CSF for both sampling and drug administration. Infection can be controlled, but not excluded, by meticulous aseptic technique. Case selection requires a clear understanding of CSF flow patterns around the CSF spaces. This has been compared favourably to the intralumbar route in studies with MTX (51), mafosfamide (52) spartaject busulfan (53), and topotecan (54,55). Furthermore, lumbar injections are often unknowingly misplaced leading to ineffective delivery to the CSF (56). It has

been demonstrated that lying flat after lumbar puncture optimizes drug distribution to upper half of the spinal cord. Intensification of lumbar administration by daily delivery is used but unpopular because of local discomfort with repeated lumbar puncture and, in children, the requirement for sedation or anaesthesia (19).

It has been hypothesized that the pharmacokinetics of the drug delivery to CSF would be best optimized by continuous infusion as opposed to bolus administration (34). A bolus administration achieves a peak concentration, followed by washout by CSF bulk flow over time. A continuous infusion would reach a plateau drug concentration throughout CSF spaces. Such an approach requires an administration device offering stable prolonged intra-CSF drug access with a portable continuous infusion pump (34) suitable for children of all ages (57). In post-operative states additional consideration needs to be given to the impact of raised intra-cranial pressure, meningitis or proteinaceous CSF interacting with CSF concentration and circulation / distribution of intra-CSF drug (58).

Despite these considerations, the standard approach to intra-CSF drug administration for leukaemia lymphoma is intermittent lumbar injection frequently under anaesthesia. The frequency of administration is intensified where frank CNS disease is seen on CSF sampling. Standard protocols deliver

intra-CSF therapy at weekly to monthly or 3-monthly intervals. The efficacy of such intervals coupled with the brief presence of the drug in the CSF due to its removal by bulk flow has not been studied pharmacologically to justify this approach. Its introduction, in combination with intensified systemic therapy to replace more damaging CNS radiation, justified the empirical adjustment to protocols (59). Multi-centre clinical trials concluded that sustained use of intra-CSF therapy without cranial radiotherapy offered acceptable CNS- relapse rates (60–62). Intrathecal therapy offers much lower rates of neuroendocrine problems and secondary tumours than craniospinal irradiation. However, prolonged intra-CSF methotrexate and/or triple therapy has been associated with adverse neurocognitive and neurobehavioural outcomes (63) and concerns are emerging about possible “accelerated aging” in the CNS 20-30 years post therapy (64).

The use of intraventricular (Ommaya reservoir) delivery of CNS-directed therapy in childhood ALL has declined over the years despite early literature, mainly from the 1970’s, reporting superior pharmacokinetics, its ease of use, and possibly increased efficacy compared to conventional lumbar delivery (65) (64). It should be noted that no randomised controlled trial of intrathecal vs intraventricular therapy has ever been performed in ALL and the literature consists of small mixed case series mainly from the 1970’s and 1980’s (56). The decline in use of Ommaya reservoirs may have been due to concerns about its usual placement for

life and the risks of CNS infection, although meticulous neurosurgical and aseptic technique has reduced these risks considerably (56,66,67).

Hydrocephalus / Ventricular shunting

For these reasons, we propose that protracted CSF infusions monitored by CSF sampling of drug concentration would be a preferable strategy in patients with shunts, a stable CSF drug concentration may be achieved allowing equilibration across the CSF spaces as long as there are no isolated cavities (figure 2). Where even distribution cannot be guaranteed, CSF flow studies prior to intra-CSF drug administration with either ¹¹¹Indium-diethylenetriamine penta-acetic acid, ⁹⁹Tc macro-aggregated albumin, or gadolinium (47,68–70) may be warranted, since standard MRI imaging might be insufficiently sensitive to assess flow characteristics in detail (69). Surgical intervention in adults has been proposed to remove bulky disease and restore CSF flow, which has been shown to prolong survival, lower treatment related morbidity and death rate from LMI (68,71,72) We are unaware of such surgical interventions being adopted in children.

Drug selection for intra-CSF delivery

Methotrexate is the most commonly used intra-CSF chemotherapy agent. This is largely due to its position as one of the first effective therapies for leukaemia in the 1950's and 1960's, rather than a critical evaluation of potential efficacy and toxicity profiles of a variety of alternative intra-CSF agents. In fact, using modern

criteria, the neurotoxicity profile of methotrexate makes it an unattractive first choice agent for intra-CSF delivery. Despite this, it has repeatedly been shown in large scale RCTs to be an effective drug for prevention of CNS relapse (60–62,73) and therefore remains widely used in ALL and lymphoma protocols (19).

Since intra-CSF therapy for brain tumours is in its infancy, there is a great opportunity to move away from methotrexate to alternative less toxic intra-CSF agents. Conroy et al (39) defined a number of required drug properties for intra-CSF administration:

1. Clinical property:

- Non-irritant
- Neurotoxicity low or absent
- Evidence of tumour sensitivity

2. Biological property:

- CSF transport system absent
- Cell cycle non-specific drugs

3. Physiochemical and pharmaceutical properties:

- Active in CSF
- Hydrophilic and/or ionised at CSF pH therefore low membrane permeability (to minimise diffusion out of CSF)
- Molecular size (>700 kDa)
- Suitable formulation readily available

Taking these characteristics into account Depocyte® (liposomal cytarabine, slow release formulation), mafosfamide (cyclophosphamide analogue), and etoposide were selected as suitable candidates for intra-CSF treatments suitable for trial in medulloblastoma (panel). Depocyte® and mafosfamide can cause chemical arachnoiditis (fever, nausea, vomiting, headache, and back pain) (74,75), justifying concomitant dexamethasone (0.15 mg/kg/dose IV or orally, twice a day for 5 days) (76–78), or low infusion rate (maximum 1 ml/min) (52). However, they have both now been withdrawn from production and are unavailable (38). Depocyte® was withdrawn due to production difficulties, whilst Mafosfamide was never fully registered as a drug and its manufacture was discontinued.

Other complications are transient such as headaches (37,43,74,79), infections of intra-CSF administration devices in <10% of patients (37,43,74,80), nausea and vomiting, seizures, and confusion (79,80). Symptomatic subacute leukoencephalopathy (confusion, somnolence or irritability, ataxia, dementia and tremor or myelopathy are rare events (37,43,79), and are more common with concurrent systemic treatment and/or radiotherapy (81–85), or CSF flow obstruction (68,69),

Use of systemic immunotherapies to target leptomeningeal infiltration

Recent advances in immunotherapies have opened up new treatment approaches for relapsed/refractory LMI in ALL. Systemically delivered chimeric antigen

receptor T cells (CAR-T cells) have been shown to home to the CNS and produce long-term remissions in patients with CNS-relapses (86). Indeed, excellent CAR-T cell expansion has been demonstrated in CSF following IV administration (87). Novel bi-specific antibodies, such as Blinatumomab (88), also have proven efficacy against CNS leukaemia. It is worth noting that these therapies are also associated with significant neurotoxicity although the exact mechanisms of this, and whether they relate to the presence of LMI or systemic cytokine release, remains unproven (89,90). In addition, other barriers to widespread adoption of immunotherapy for LMI in ALL are large treatment costs and the current lack of effective agents against T-ALL (which has higher rates of refractory LMI than B-ALL).

When evaluating new products, the degree of CNS-homing of different classes of immunotherapy should be taken into account. In contrast, to CAR-T and bispecific antibodies, NK-based therapies (91) and monoclonal antibodies such as Rituximab may not be able to cross into the CSF without direct intra-CSF delivery (92).

The application of immune strategies in brain tumours is in early development preliminary experience is limited to exploration of the use of intrathecally delivered immune-stimulants such as Interleukin 2 and interferon beta (93). Intraventricular administration of radio-immunotherapy using (131) I-3F8 in

medulloblastoma has been shown to be safe and feasible and could be used to complement other therapies in the future (94).

Future directions for treatment of LMI

Haematological malignancies

Interestingly, the use of intra-CSF therapy for haematological malignancies and brain tumours appear to be going in opposite directions. In haematological malignancies, the focus is on optimising the use of systemic drugs with good CSF penetration and concomitantly reducing the burden, and, potentially, the toxicity of intra-CSF therapy. Whereas in brain tumours, judicious use of CSF directed therapy for LMI is gaining importance with an associated focus on other CNS directed drug delivery techniques to try to enhance efficacy of drug therapy for primary brain tumours.

Despite this, many opportunities for advances in treatment of LMI in ALL exist. Firstly, sensitive biomarkers need to be developed to allow accurate detection of LMI and to track its response to initial CNS-directed therapy. Once available, future studies would be able to use these biomarkers to test de-escalation of CNS directed therapy for patients at low risk of CNS relapse, thus significantly reducing their exposure to currently used neurotoxic agents. A move away from methotrexate to either less neurotoxic cytotoxic agents such as cytarabine, etoposide, topotecan or carboplatin, or newer targeted, non-neurotoxic treatments

for intra-CSF delivery would benefit all patients, but the immense difficulties in switching from an efficacious (albeit toxic) agent to an unproven novel agent are not to be underestimated.

Advances in this area are likely to be seen by testing existing previously unused agents via the intra-CSF route as well as novel agents, as bolus or infusional therapy, in cases of relapsed or refractory disease. The point of drug delivery may need to be reconsidered. Although, systemic immunotherapy may prove to be the first-line choice in leukaemias it will be limited by cost, toxicity and lack of efficacy against T-ALL.

CNS malignancies

In brain tumours, taking the lead from haematological malignancies, the priority is to sustain control of LM disease whilst reducing the burden of morbidity and late consequences particularly of radiation therapy to the cranio-spinal axis. One way this could be achieved would be to establish devices and techniques to deliver infusional intra-CSF therapy and explore the most suitable existing and new agents emerging from research and development for this route of administration. Ninety percent of new cancer drugs do not cross the blood brain barrier sufficiently for an effect to be anticipated by systemic administration. Such drugs delivered directly to the CSF may have a much greater impact. Their exploration in trials via the intra-CSF route should be prioritized involving

children with specific requirement to avoid the serious neuro-toxicity of cranio-spinal radiotherapy in pre-school age children and in children with relapsed disease initially, once feasibility of intra-CSF administration is established.

Priorities for future research

Perhaps the most important developments is a commitment to identify new effective and less toxic drugs, and safe and easy systems for their delivery, to target malignancies in the LMI. The proposed infusional intra-CSF studies are being pursued with the intent of developing a platform for their testing and selection of drugs for further development. Sustained release systems such as Depocyte® offered a sustained profile after a single injection. An expanded range of such preparations with targeted agents is an attractive prospect. Sharing delivery systems and target selection with the needs of adult practice would create synergy for their commercial development.

Search strategy and selection criteria

Relevant literature was identified using PubMed and article reference lists. Search terms comprised leptomeningeal, paediatric, adolescent, cancer, leukaemia, brain tumour, medulloblastoma, cerebrospinal fluid and drug-delivery. Search was restricted to English language with no date restrictions

Author contribution:

CH - Performed literature search and contributed to writing of manuscript

LM – Performed literature search and contributed to writing of manuscript

DAW – Conceived of the need for the review and contributed to writing of manuscript

BC – Contributed to writing of manuscript

Reference list

1. Paterson E, Farr RF. Cerebellar medulloblastoma: Treatment by irradiation of the whole central nervous system. *Acta radiol.* 1953;39(4):323–36.
2. Bloom HJ, Wallace EN, Henk JM. The treatment and prognosis of medulloblastoma in children. A study of 82 verified cases. *Am J Roentgenol Radium Ther Nucl Med.* 1969 Jan;105(1):43–62.
3. Merchant TE, Pollack IF, Loeffler JS. Brain tumors across the age spectrum: biology, therapy, and late effects. *Semin Radiat Oncol* [Internet]. 2010 Jan [cited 2012 Nov 29];20(1):58–66. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/19959032>
4. Ramaswamy V, Remke M, Bouffet E, Bailey S, Clifford SC, Doz F, et al. Risk stratification of childhood medulloblastoma in the molecular era: the current consensus [Internet]. Vol. 131, *Acta Neuropathologica.* 2016. p. 821–31. Available from: <http://link.springer.de/link/service/journals/00401/index.htm%5Cnhttp://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed18a&NEWS=N&AN=609609673>
5. Pajtler KW, Tippelt S, Siegler N, Reichling S, Zimmermann M, Mikasch R, et al. Intraventricular etoposide safety and toxicity profile in children and young adults with refractory or recurrent malignant brain tumors. *J Neurooncol* [Internet]. 2016 May 4 [cited 2016 May 13];128(3):463–71.

Available from: <http://www.ncbi.nlm.nih.gov/pubmed/27147083>

6. Pompe RS, Von Bueren AO, Mynarek M, Von Hoff K, Friedrich C, Kwiecien R, et al. Intraventricular methotrexate as part of primary therapy for children with infant and/or metastatic medulloblastoma: Feasibility, acute toxicity and evidence for efficacy. *Eur J Cancer*. 2015;51(17):2634–42.
7. Von Bueren AO, Kortmann RD, Von Hoff K, Friedrich C, Mynarek M, Müller K, et al. Treatment of children and adolescents with metastatic medulloblastoma and prognostic relevance of clinical and biologic parameters. *J Clin Oncol*. 2016;34(34):4151–60.
8. Chi SN, Zimmerman MA, Yao X, Cohen KJ, Burger P, Biegel J a, et al. Intensive multimodality treatment for children with newly diagnosed CNS atypical teratoid rhabdoid tumor. *J Clin Oncol* [Internet]. 2009 Jan 20 [cited 2012 Nov 1];27(3):385–9. Available from: <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2645855&tool=pmcentrez&rendertype=abstract>
9. Peyrl A, Chocholous M, Kieran MW, Azizi AA, Prucker C, Czech T, et al. Antiangiogenic metronomic therapy for children with recurrent embryonal brain tumors. *Pediatr Blood Cancer* [Internet]. 2012 Sep [cited 2013 Apr 16];59(3):511–7. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/22147459>
10. Athale UH, Duckworth J, Odame I, Barr R. Childhood atypical teratoid

- rhabdoid tumor of the central nervous system: a meta-analysis of observational studies. *J Pediatr Hematol Oncol* [Internet]. 2009 Sep [cited 2013 Apr 10];31(9):651–63. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/19707161>
11. Lafay-Cousin L, Bouffet E, Onar-Thomas A, Billups CA, Hawkins C, Eberhart C, et al. ACNS1221: A phase II study for the treatment of non metastatic desmoplastic medulloblastoma in children less than 4 years of age-A report from the Children Oncology Group. *J Clin Oncol* [Internet]. 2017;35(15). Available from: <http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L617388902>
 12. Rutkowski S, Gerber NU, von Hoff K, Gnekow A, Bode U, Graf N, et al. Treatment of early childhood medulloblastoma by postoperative chemotherapy and deferred radiotherapy. *Neuro Oncol* [Internet]. 2009 Apr [cited 2013 Jun 13];11(2):201–10. Available from: <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2718992&tool=pmcentrez&rendertype=abstract>
 13. Robinson GW, Rudneva VA, Buchhalter I, Billups CA, Waszak SM, Smith KS, et al. Risk-adapted therapy for young children with medulloblastoma (SJYC07): therapeutic and molecular outcomes from a multicentre, phase 2 trial. *Lancet Oncol* [Internet]. 2018;19Partap(6Stewart):768–84. Available from:

[http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L2000774422%0Ahttp://dx.doi.org/10.1016/S1470-2045\(18\)30204-3](http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L2000774422%0Ahttp://dx.doi.org/10.1016/S1470-2045(18)30204-3)

14. Bruna J, Simó M, Velasco R. Leptomeningeal Metastases. *Curr Treat Options Neurol* [Internet]. 2012 Jun 27 [cited 2015 Oct 10];14(4):402–15. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/22736147>
15. Yao H, Price TT, Cantelli G, Ngo B, Warner MJ, Olivere L, et al. Leukaemia hijacks a neural mechanism to invade the central nervous system. *Nature*. 2018;560(7716):55–60.
16. Williams MTS, Yousafzai YM, Elder A, Rehe K, Bomken S, Frishman-Levy L, et al. The ability to cross the blood-cerebrospinal fluid barrier is a generic property of acute lymphoblastic leukemia blasts. *Blood* [Internet]. 2016;127(16):1998–2006. Available from: <http://www.bloodjournal.org/content/bloodjournal/127/16/1998.full.pdf?scope-checked=true%0Ahttp://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed17&NEWS=N&AN=616373611>
17. Bartram J, Goulden N, Wright G, Adams S, Brooks T, Edwards D, et al. High throughput sequencing in acute lymphoblastic leukemia reveals clonal architecture of central nervous system and bone marrow compartments. *Vol. 103, Haematologica*. 2018. p. e110–4.
18. Frishman-Levy L, Izraeli S. Advances in understanding the pathogenesis of

- CNS acute lymphoblastic leukaemia and potential for therapy. Vol. 176, British Journal of Haematology. 2017. p. 157–67.
19. Pui CH, Howard SC. Current management and challenges of malignant disease in the CNS in paediatric leukaemia. Vol. 9, The Lancet Oncology. 2008. p. 257–68.
 20. Hunger Stephen, Mullighan Charles. Acute Lymphoblastic Leukemia in Children [Internet]. Vol. 373, New England Journal of Medicine. 2015 [cited 2015 Oct 27]. p. 1541–52. Available from: <http://www.nejm.org/doi/full/10.1056/NEJMra1400972>
 21. Cheung YT, Krull KR. Neurocognitive outcomes in long-term survivors of childhood acute lymphoblastic leukemia treated on contemporary treatment protocols: A systematic review. Neurosci Biobehav Rev [Internet]. 2015;53:108–20. Available from: <http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L603689457%5Cnhttp://dx.doi.org/10.1016/j.neubiorev.2015.03.016>
 22. Halsey C, Buck G, Richards S, Vargha-Khadem F, Hill F, Gibson B. The impact of therapy for childhood acute lymphoblastic leukaemia on intelligence quotients; Results of the risk-stratified randomized central nervous system treatment trial MRC UKALL XI. J Hematol Oncol. 2011;4.
 23. Fouladi M, Gajjar A, Boyett JM, Walter AW, Thompson SJ, Merchant TE, et al. Comparison of CSF cytology and spinal magnetic resonance imaging

- in the detection of leptomeningeal disease in pediatric medulloblastoma or primitive neuroectodermal tumor. *J Clin Oncol* [Internet]. 1999 Oct [cited 2013 Sep 4];17(10):3234–7. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/10506624>
24. Suki D, Hatiboglu MA, Patel AJ, Weinberg JS, Groves MD, Mahajan A, et al. Comparative risk of leptomeningeal dissemination of cancer after surgery or stereotactic radiosurgery for a single supratentorial solid tumor metastasis. *Neurosurgery* [Internet]. 2009 Apr [cited 2013 Oct 11];64(4):664-74-6. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/19197219>
 25. Zapotocky M, Mata-Mbemba D, Sumerauer D, Liby P, Lassaletta A, Zamecnik J, et al. Differential patterns of metastatic dissemination across medulloblastoma subgroups. *J Neurosurg Pediatr*. 2017;21(2):145–52.
 26. Morrissy AS, Garzia L, Shih DJH, Zuyderduyn S, Huang X, Skowron P, et al. Divergent clonal selection dominates medulloblastoma at recurrence. *Nature*. 2016;529(7586):351–7.
 27. Morrissy AS, Cavalli FMG, Remke M, Ramaswamy V, Shih DJH, Holgado BL, et al. Spatial heterogeneity in medulloblastoma. *Nat Genet*. 2017;49(5):780–8.
 28. Ramaswamy V, Taylor MD. Medulloblastoma: From myth to molecular. Vol. 35, *Journal of Clinical Oncology*. 2017. p. 2355–63.
 29. Garzia L, Kijima N, Morrissy AS, De Antonellis P, Guerreiro-Stucklin A,

- Holgado BL, et al. A Hematogenous Route for Medulloblastoma Leptomeningeal Metastases. *Cell*. 2018;172(5):1050–1054.e14.
30. Garzia L, Kijima N, Morrissy AS, De Antonellis P, Guerreiro-Stucklin A, Holgado BL, et al. Erratum: A Hematogenous Route for Medulloblastoma Leptomeningeal Metastases (S0092867418301156 (2018) 172(5) (1050–1062.e14) (S0092867418301156) (10.1016/j.cell.2018.01.038)). Vol. 173, *Cell*. 2018. p. 1549.
31. Abbott NJ, Rönnbäck L, Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier. *Nat Rev Neurosci* [Internet]. 2006 Jan [cited 2012 Mar 3];7(1):41–53. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/16371949>
32. Johanson CE, Duncan JA, Stopa EG, Baird A. Enhanced prospects for drug delivery and brain targeting by the choroid plexus-CSF route. *Pharm Res* [Internet]. 2005 Jul [cited 2013 Sep 24];22(7):1011–37. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/16028003>
33. Pardridge WM. Blood-brain barrier drug targeting: the future of brain drug development. *Mol Interv* [Internet]. 2003 Mar [cited 2013 Sep 26];3(2):90–105, 51. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/14993430>
34. Huynh GH, Deen DF, Szoka FC. Barriers to carrier mediated drug and gene delivery to brain tumors. *J Control Release* [Internet]. 2006 Jan 10 [cited 2013 Aug 23];110(2):236–59. Available from: <http://dx.doi.org/10.1016/j.jconrel.2005.09.053>

35. Murphy SB, Bowman WP, Abromowitch M, Mirro J, Ochs J, Rivera G, et al. Results of treatment of advanced-stage Burkitt's lymphoma and B cell (SIg+) acute lymphoblastic leukemia with high-dose fractionated cyclophosphamide and coordinated high-dose methotrexate and cytarabine. *J Clin Oncol.* 1986;4(12):1732–9.
36. Main C, Wilson JS, Stevens SP, Houlton AE, English M, Kearns PR, et al. The role of high-dose myeloablative chemotherapy with haematopoietic stem cell transplantation (HSCT) in children with central nervous system (CNS) tumours: Protocol for a systematic review and meta-analysis. *Syst Rev.* 2015;4(1).
37. Fleischhack G, Reif S, Hasan C, Jaehde U, Hettmer S, Bode U. Feasibility of intraventricular administration of etoposide in patients with metastatic brain tumours. *Br J Cancer [Internet].* 2001 Jun 1;84(11):1453–9. Available from:
<http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2363656&tool=pmcentrez&rendertype=abstract>
38. Elvidge S. Pacira halts production of Depocyte [Internet]. BioPharmaDIVE: Manufacturing. 2017. Available from:
<https://www.biopharmadive.com/news/pacira-depocyt-end-production-discontinue/446507/>
39. Conroy S, Garnett M, Vloeberghs M, Grundy R, Craven I, Walker D. Medulloblastoma in childhood: revisiting intrathecal therapy in infants and

- children. *Cancer Chemother Pharmacol* [Internet]. 2010 May [cited 2012 May 11];65(6):1173–89. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/19855967>
40. Rutkowski S, Bode U, Deinlein F, Ottensmeier H, Warmuth-Metz M, Soerensen N, et al. Treatment of early childhood medulloblastoma by postoperative chemotherapy alone. *N Engl J Med* [Internet]. 2005 Mar 10 [cited 2013 Sep 23];352(10):978–86. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/15758008>
41. Moxon-Emre I, Bouffet E, Taylor MD, Laperriere N, Scantlebury N, Law N, et al. Impact of craniospinal dose, boost volume, and neurologic complications on intellectual outcome in patients with medulloblastoma. *J Clin Oncol* [Internet]. 2014 Jun 10 [cited 2015 Mar 3];32(17):1760–8. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/24516024>
42. Habgood MD, Begley DJ, Abbott NJ. Determinants of passive drug entry into the central nervous system. *Cell Mol Neurobiol* [Internet]. 2000 Apr [cited 2013 Sep 12];20(2):231–53. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/10696512>
43. Chamberlain MC. Pediatric leptomeningeal metastases: outcome following combined therapy. *J Child Neurol* [Internet]. 1997 Jan;12(1):53–9. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/9010796>
44. Bleyer WA. Biology and pathogenesis of CNS leukemia. *Am J Pediatr Hematol Oncol* [Internet]. 1989 Jan [cited 2013 Sep 26];11(1):57–63.

Available from: <http://www.ncbi.nlm.nih.gov/pubmed/2712245>

45. Sirisangtragul C. Pharmacokinetics and pharmacodynamics of intraventricularly administered Etoposide [Internet]. 2007. Available from: http://hss.ulb.uni-bonn.de/diss_online_elektronisch_publiziert
46. Howden L, Giddings D, Power H, Aroussi A, Vloeberghs M, Garnett M, et al. Three-dimensional cerebrospinal fluid flow within the human ventricular system. *Comput Methods Biomech Biomed Engin* [Internet]. 2008 Apr [cited 2013 Feb 5];11(2):123–33. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/18297492>
47. Chamberlain MC. Radioisotope CSF flow studies in leptomeningeal metastases. *J Neurooncol* [Internet]. 1998 [cited 2013 Sep 13];38(2–3):135–40. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/9696363>
48. Merchant TE, Hodgson D, Laack NNI, Wolden S, Indelicato DJ, Kalapurakal JA. Children’s Oncology Group’s 2013 blueprint for research: radiation oncology. *Pediatr Blood Cancer* [Internet]. 2013 Jun [cited 2013 Jun 17];60(6):1037–43. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/23255526>
49. Clayton J, Vloeberghs M, Jaspan T, Walker D, MacArthur D, Grundy R. Intrathecal chemotherapy delivered by a lumbar-thecal catheter in metastatic medulloblastoma: a case illustration. *Acta Neurochir (Wien)* [Internet]. 2008 Jul [cited 2013 Feb 5];150(7):709–12. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/18401539>

50. Lord P, Allami H, Davis M, Diaz R, Heck P, Fischell R. MiniMed Technologies Programmable Implantable Infusion System. *Ann N Y Acad Sci* [Internet]. 1988 Jan [cited 2013 Sep 25];531:66–71. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/3289460>
51. Shapiro WR, Young DF, Mehta BM. Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections. *N Engl J Med* [Internet]. 1975 Jul 24 [cited 2012 Dec 17];293(4):161–6. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/806016>
52. Blaney SM, Balis FM, Berg S, Arndt CAS, Heideman R, Geyer JR, et al. Intrathecal mafosfamide: a preclinical pharmacology and phase I trial. *J Clin Oncol* [Internet]. 2005 Mar 1 [cited 2012 Nov 14];23(7):1555–63. Available from: <http://europepmc.org/abstract/MED/15735131>
53. Gururangan S, Petros WP, Poussaint TY, Hancock ML, Phillips PC, Friedman HS, et al. Phase I trial of intrathecal spartaject busulfan in children with neoplastic meningitis: a Pediatric Brain Tumor Consortium Study (PBTC-004). *Clin Cancer Res* [Internet]. 2006 Mar 1 [cited 2012 Nov 6];12(5):1540–6. Available from: <http://clincancerres.aacrjournals.org/content/12/5/1540.short>
54. Potter SLP, Berg S, Ingle AM, Krailo M, Adamson PC, Blaney SM, et al. Phase 2 Clinical Trial of Intrathecal Topotecan in Children With Refractory Leptomeningeal Leukemia : A Children ' s Oncology Group Trial (P9962). *Pediatr Blood Cancer* [Internet]. 2012 Mar [cited 2013 Oct 9];58(3):362–

5. Available from:
<http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3242923&tool=pmcentrez&rendertype=abstract>
55. Blaney SM, Tagen M, Onar-Thomas A, Berg SL, Gururangan S, Scorsone K, et al. A phase-1 pharmacokinetic optimal dosing study of intraventricular topotecan for children with neoplastic meningitis: A pediatric brain tumor consortium study. *Pediatr Blood Cancer*. 2013;60(4):627–32.
56. Wilson R, Osborne C, Halsey C. The Use of Ommaya Reservoirs to Deliver Central Nervous System-Directed Chemotherapy in Childhood Acute Lymphoblastic Leukaemia. *Pediatr Drugs*. 2018;20(4):293–301.
57. Heruth KT. Medtronic SynchroMed drug administration system. *Ann N Y Acad Sci* [Internet]. 1988 Jan [cited 2013 Sep 25];531:72–5. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/3289461>
58. Magrath IT, Bleyer WA, Poplack DG, Glaubiger DL, Bode U. Active transport of methotrexate from cerebrospinal fluid in humans. *Cancer Res*. 1980;40(7):2184–7.
59. Hill FGH, Richards S, Gibson B, Hann I, Lilleyman J, Kinsey S, et al. Successful treatment without cranial radiotherapy of children receiving intensified chemotherapy for acute lymphoblastic leukaemia: Results of the risk-stratified randomized central nervous system treatment trial MRC UKALL XI (ISRC TN 16757172). *Br J Haematol*. 2004;124(1):33–46.

60. Pui C-H, Sandlund JT, Pei D, Campana D, Rivera GK, Ribeiro RC, et al. Improved outcome for children with acute lymphoblastic leukemia: Results of Total Therapy Study XIII B at St Jude Children's Research Hospital. *Blood* [Internet]. 2004;104(9):2690–6. Available from: <http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L39434949%5Cnhttp://dx.doi.org/10.1182/blood-2004-04-1616%5Cnhttp://elvis.ubvu.vu.nl:9003/vulink?sid=EMBASE&issn=00064971&id=doi:10.1182%2Fblood-2004-04-1616&atitle=Improved+outcome+>
61. Schrappe M, Moricke A, Reiter A, Zimmermann M, Gadner H, Stanulla M, et al. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. *Blood*. 2008;111(9):4477–89.
62. Moghrabi, Albert; Levy. Donna; Asselin B et. al., Moghrabi A, Levy DE, Asselin B, Barr R, Clavell L, et al. Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. *Blood*. 2007;109(3):896–904.
63. Cheung YT, Sabin ND, Reddick WE, Bhojwani D, Liu W, Brinkman TM, et al. Leukoencephalopathy and long-term neurobehavioural, neurocognitive, and brain imaging outcomes in survivors of childhood acute lymphoblastic leukaemia treated with chemotherapy: a longitudinal

- analysis. *Lancet Haematol* [Internet]. 2016;3(10):e456–66. Available from: [http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L613223480%5Cnhttp://dx.doi.org/10.1016/S2352-3026\(16\)30110-7%5Cnhttp://sfx.library.uu.nl/utrecht?sid=EMBASE&issn=23523026&id=doi:10.1016%2FS2352-3026%2816%2930110-7&atitle=Leukoence](http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L613223480%5Cnhttp://dx.doi.org/10.1016/S2352-3026(16)30110-7%5Cnhttp://sfx.library.uu.nl/utrecht?sid=EMBASE&issn=23523026&id=doi:10.1016%2FS2352-3026%2816%2930110-7&atitle=Leukoence)
64. Zeller B, Tamnes CK, Kanellopoulos A, Amlien IK, Andersson S, Due-Tønnessen P, et al. Reduced neuroanatomic volumes in long-term survivors of childhood acute lymphoblastic leukemia. *J Clin Oncol* [Internet]. 2013 Jun 10 [cited 2013 Aug 23];31(17):2078–85. Available from: <http://jco.ascopubs.org/content/31/17/2078>
65. Gaynon PS, Angiolillo AL, Carroll WL, Nachman JB, Trigg ME, Sather HN, et al. Long-term results of the children’s cancer group studies for childhood acute lymphoblastic leukemia 1983-2002: a Children’s Oncology Group Report. *Leukemia* [Internet]. 2010 Feb [cited 2013 Oct 11];24(2):285–97. Available from: <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2906139&tool=pmcentrez&rendertype=abstract>
66. Peyrl A, Chocholous M, Azizi AA, Czech T, Dorfer C, Mitteregger D, et al. Safety of Ommaya reservoirs in children with brain tumors: a 20-year experience with 5472 intraventricular drug administrations in 98 patients. *J Neurooncol* [Internet]. 2014 Jul 14 [cited 2015 Oct 10];120(1):139–45. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/25017328>

67. Mead PA, Safdieh JE, Nizza P, Tuma S, Sepkowitz KA. Ommaya reservoir infections: A 16-year retrospective analysis. *J Infect*. 2014;68(3):225–30.
68. Glantz MJ, Hall WA, Cole BF, Chozick BS, Shannon CM, Wahlberg L, et al. Diagnosis, management, and survival of patients with leptomeningeal cancer based on cerebrospinal fluid-flow status. *Cancer* [Internet]. 1995 Jun 15 [cited 2013 Sep 12];75(12):2919–31. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/7773943>
69. Grossman SA, Krabak MJ. Leptomeningeal carcinomatosis. *Cancer Treat Rev* [Internet]. 1999 Apr [cited 2013 Sep 19];25(2):103–19. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/10395835>
70. Chamberlain MC, Kormanik P, Jaeckle KA, Glantz M, Mason WP, Yeh SD, et al. 111Indium-diethylenetriamine pentaacetic acid CSF flow studies predict distribution of intrathecally administered chemotherapy and outcome in patients with leptomeningeal metastases. *Neurology* [Internet]. 1999 Jan 1 [cited 2013 Sep 12];52(1):216–7. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/9921888>
71. Grossman SA, Trump DL, Chen DC, Thompson G, Camargo EE. Cerebrospinal fluid flow abnormalities in patients with neoplastic meningitis. An evaluation using 111indium-DTPA ventriculography. *Am J Med* [Internet]. 1982 Nov [cited 2013 Sep 12];73(5):641–7. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/6814249>
72. Mason WP, Yeh SD, DeAngelis LM. 111Indium-diethylenetriamine

pentaacetic acid cerebrospinal fluid flow studies predict distribution of intrathecally administered chemotherapy and outcome in patients with leptomeningeal metastases. *Neurology* [Internet]. 1998 Feb [cited 2013 Sep 12];50(2):438–44. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/9484369>

73. Richards S, Pui C-H, Gayon P. Systematic review and meta-analysis of randomized trials of central nervous system directed therapy for childhood acute lymphoblastic leukemia. *Pediatr Blood Cancer* [Internet]. 2013 Feb [cited 2013 Oct 10];60(2):185–95. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/22693038>
74. Blaney SM, Tagen M, Onar-Thomas A, Berg SL, Gururangan S, Scorsone K, et al. A phase-1 pharmacokinetic optimal dosing study of intraventricular topotecan for children with neoplastic meningitis: A pediatric brain tumor consortium study. *Pediatr Blood Cancer* [Internet]. 2012 Sep 21 [cited 2013 Feb 14]; Available from: <http://www.ncbi.nlm.nih.gov/pubmed/23002039>
75. Sancho J-M, Ribera J-M, Romero M-J, Martín-Reina V, Giraldo P, Ruiz E. Compassionate use of intrathecal depot liposomal cytarabine as treatment of central nervous system involvement in acute leukemia: report of 6 cases. *Haematologica* [Internet]. 2006 Mar 1 [cited 2012 Nov 6];91(3):ECR02. Available from: <http://www.haematologica.org/content/91/3/ECR02.abstract>

76. Bomgaars L, Geyer JR, Franklin J, Dahl G, Park J, Winick NJ, et al. Phase I trial of intrathecal liposomal cytarabine in children with neoplastic meningitis. *J Clin Oncol* [Internet]. 2004 Oct 1 [cited 2012 Apr 1];22(19):3916–21. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/15459213>
77. Glantz MJ, LaFollette S, Jaeckle KA, Shapiro W, Swinnen L, Rozental JR, et al. Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. *J Clin Oncol* [Internet]. 1999 Oct [cited 2013 Sep 26];17(10):3110–6. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/10506606>
78. Glantz MJ, Jaeckle KA, Chamberlain MC, Phuphanich S, Recht L, Swinnen LJ, et al. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. *Clin Cancer Res* [Internet]. 1999 Nov [cited 2013 Sep 20];5(11):3394–402. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/10589750>
79. Waki F, Ando M, Takashima A, Yonemori K, Nokihara H, Miyake M, et al. Prognostic factors and clinical outcomes in patients with leptomeningeal metastasis from solid tumors. *J Neurooncol* [Internet]. 2009 Jun [cited 2013 Feb 14];93(2):205–12. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/19043775>
80. Nakagawa H, Miyahara E, Suzuki T, Wada K, Tamura M, Fukushima Y.

- Continuous intrathecal administration of 5-fluoro-2'-deoxyuridine for the treatment of neoplastic meningitis. *Neurosurgery* [Internet]. 2005 Aug [cited 2013 Apr 9];57(2):266-80-80. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/16094155>
81. Ruggiero a, Conter V, Milani M, Biagi E, Lazzareschi I, Sparano P, et al. Intrathecal chemotherapy with antineoplastic agents in children. *Paediatr Drugs* [Internet]. 2001 Jan;3(4):237-46. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/11354696>
82. Ostermann K, Pels H, Kowoll A, Kuhnenn J, Schlegel U. Neurologic complications after intrathecal liposomal cytarabine in combination with systemic polychemotherapy in primary CNS lymphoma. *J Neurooncol* [Internet]. 2011 Jul [cited 2012 Nov 6];103(3):635-40. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/20953896>
83. Boogerd W, van den Bent MJ, Koehler PJ, Heimans JJ, van der Sande JJ, Aaronson NK, et al. The relevance of intraventricular chemotherapy for leptomeningeal metastasis in breast cancer: a randomised study. *Eur J Cancer* [Internet]. 2004 Dec [cited 2013 Sep 26];40(18):2726-33. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/15571954>
84. Rubinstein LJ, Herman MM, Long TF, Wilbur JR. Disseminated necrotizing leukoencephalopathy: a complication of treated central nervous system leukemia and lymphoma. *Cancer* [Internet]. 1975 Feb [cited 2013 Sep 26];35(2):291-305. Available from:

<http://www.ncbi.nlm.nih.gov/pubmed/1053934>

85. Siegal T, Lossos A, Pfeffer MR. Leptomeningeal metastases: analysis of 31 patients with sustained off-therapy response following combined-modality therapy. *Neurology* [Internet]. 1994 Aug [cited 2013 Sep 26];44(8):1463–9. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/8058150>
86. Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. *N Engl J Med* [Internet]. 2018;378(5):439–48. Available from: <http://www.nejm.org/doi/10.1056/NEJMoa1709866>
87. Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. *N Engl J Med* [Internet]. 2014;371(16):1507–17. Available from: <http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L600227978%0Ahttp://dx.doi.org/10.1056/NEJMoa1407222%0Ahttp://sfx10.usaco.co.jp/ncchd?sid=EMBASE&issn=15334406&id=doi:10.1056%2FNEJMoa1407222&atitle=Chimeric+antigen+receptor+T+cells>
88. Topp MS, Gokbuget N, Zugmaier G, Klappers P, Stelljes M, Neumann S, et al. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. *J Clin Oncol* [Internet]. 2014;32(36):4134–40. Available from: <http://jco.ascopubs.org/content/32/36/4134.full.pdf+html%0Ahttp://ovidsp>

ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed16&NEWS=N&
AN=601019576

89. Santomasso BD, Park JH, Salloum D, Riviere I, Flynn J, Mead E, et al. Clinical and biological correlates of neurotoxicity associated with car t-cell therapy in patients with B-cell acute lymphoblastic leukemia. *Cancer Discov.* 2018;8(8):958–71.
90. Stein AS, Schiller G, Benjamin R, Jia C, Zhang A, Zhu M, et al. Neurologic adverse events in patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab: management and mitigating factors. *Annals of Hematology.* 2018;
91. Frishman-Levy L, Shemesh A, Bar-Sinai A, Ma C, Ni Z, Frenkel S, et al. Central nervous system acute lymphoblastic leukemia: Role of natural killer cells. *Blood.* 2015;125(22):3420–31.
92. Wada-Shimosato Y, Ikeda J, Tsujimoto S-I, Sasaki K, Yanagimachi M, Kajiwara R, et al. Intraventricular Rituximab in Pediatric CD20-positive Refractory Primary Central Nervous System Lymphoma. *J Pediatr Hematol Oncol.* 2018 Aug;
93. McGranahan T, Li G, Nagpal S. History and current state of immunotherapy in glioma and brain metastasis. *Ther Adv Med Oncol.* 2017 May;9(5):347–68.
94. Kramer K, Pandit-Taskar N, Humm JL, Zanzonico PB, Haque S, Dunkel IJ, et al. A phase II study of radioimmunotherapy with intraventricular





Figure 1: Mechanisms of leptomeningeal dissemination from primary brain tumors via CSF or haematogenous routes

Adapted from ref 29. [Note: this is from Cell (published by Elsevier) and open access, so no need to ask for permission. We will remove the mouse and change the adult to a child]



Blue is cerebrospinal fluid space
Red is blood space

Figure 2: Routes of administration for intra-CSF therapy (VR - ventricular route; LR – lumbar route). LR can be used in patients with ventriculoperitoneal shunts

Panel: Drugs graded by eligibility for trial by intrathecal administration for medulloblastoma (ref 37 - Conroy et al 2010)

Agents under trial

- Liposomal cytarabine (Depocyte®)*
- Mafosfamide*

Agents suitable for clinical trial

- Carboplatin
- Etoposide

Nimustine (ACNU)

Drugs requiring further investigation before clinical trial

Floxuridine (FDUrd)

4-hydroperoxy-cyclophosphamide

Drugs requiring further investigation, lower priority

Diaziquone

Mercaptopurine

Rubitecan

Topotecan

Radio-immunotherapy ¹³¹I-3F8 murine monoclonal antibody

Drug with insufficient information to grade

Temozolomide

* This drug has now been withdrawn from production by the manufacturer